Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 5/2024

14.12.2023 | Original Article

A convolutional neural network–based system for fully automatic segmentation of whole-body [68Ga]Ga-PSMA PET images in prostate cancer

verfasst von: Esmail Jafari, Amin Zarei, Habibollah Dadgar, Ahmad Keshavarz, Reyhaneh Manafi-Farid, Habib Rostami, Majid Assadi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was development and evaluation of a fully automated tool for the detection and segmentation of mPCa lesions in whole-body [68Ga]Ga-PSMA-11 PET scans by using a nnU-Net framework.

Methods

In this multicenter study, a cohort of 412 patients from three different center with all indication of PCa who underwent [68Ga]Ga-PSMA-11 PET/CT were enrolled. Two hundred cases of center 1 dataset were used for training the model. A fully 3D convolutional neural network (CNN) is proposed which is based on the self-configuring nnU-Net framework. A subset of center 1 dataset and cases of center 2 and center 3 were used for testing of model. The performance of the segmentation pipeline that was developed was evaluated by comparing the fully automatic segmentation mask with the manual segmentation of the corresponding internal and external test sets in three levels including patient-level scan classification, lesion-level detection, and voxel-level segmentation. In addition, for comparison of PET-derived quantitative biomarkers between automated and manual segmentation, whole-body PSMA tumor volume (PSMA-TV) and total lesions PSMA uptake (TL-PSMA) were calculated.

Results

In terms of patient-level classification, the model achieved an accuracy of 83%, sensitivity of 92%, PPV of 77%, and NPV of 91% for the internal testing set. For lesion-level detection, the model achieved an accuracy of 87–94%, sensitivity of 88–95%, PPV of 98–100%, and F1-score of 93–97% for all testing sets. For voxel-level segmentation, the automated method achieved average values of 65–70% for DSC, 72–79% for PPV, 53–58% for IoU, and 62–73% for sensitivity in all testing sets. In the evaluation of volumetric parameters, there was a strong correlation between the manual and automated measurements of PSMA-TV and TL-PSMA for all centers.

Conclusions

The deep learning networks presented here offer promising solutions for automatically segmenting malignant lesions in prostate cancer patients using [68Ga]Ga-PSMA PET. These networks achieve a high level of accuracy in whole-body segmentation, as measured by the DSC and PPV at the voxel level. The resulting segmentations can be used for extraction of PET-derived quantitative biomarkers and utilized for treatment response assessment and radiomic studies.
Literatur
1.
Zurück zum Zitat Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30:628–36.CrossRefPubMed Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30:628–36.CrossRefPubMed
2.
Zurück zum Zitat Dadgar H, Seyedi Vafaee M, Norouzbeigi N, Jafari E, Gholamrezanezhad A, Assadi M. Dual-phase 68Ga-PSMA-11 PET/CT may increase the rate of detected lesions in prostate cancer patients. Urol J: SAGE Publications Ltd STM; 2021. p. 0391560321993544. Dadgar H, Seyedi Vafaee M, Norouzbeigi N, Jafari E, Gholamrezanezhad A, Assadi M. Dual-phase 68Ga-PSMA-11 PET/CT may increase the rate of detected lesions in prostate cancer patients. Urol J: SAGE Publications Ltd STM; 2021. p. 0391560321993544.
3.
Zurück zum Zitat Jafari E, Ahmadzadehfar H, Dadgar H, Assadi M. An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: a pictorial essay. World J Nucl Med. 2020;19(03):260–5.CrossRefPubMedPubMedCentral Jafari E, Ahmadzadehfar H, Dadgar H, Assadi M. An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: a pictorial essay. World J Nucl Med. 2020;19(03):260–5.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Jokar N, Velikyan I, Ahmadzadehfar H, Rekabpour SJ, Jafari E, Ting HH, et al. Theranostic approach in breast cancer: a treasured tailor for future oncology. Clin Nucl Med. 2021;46(8):e410–20.CrossRefPubMed Jokar N, Velikyan I, Ahmadzadehfar H, Rekabpour SJ, Jafari E, Ting HH, et al. Theranostic approach in breast cancer: a treasured tailor for future oncology. Clin Nucl Med. 2021;46(8):e410–20.CrossRefPubMed
5.
Zurück zum Zitat Jokar N, Moradhaseli F, Ahmadzadehfar H, Jafari E, Nikeghbalian S, Rasekhi AR, et al. Theranostic approach in liver cancer: an emerging paradigm to optimize personalized medicine. Clin Transl Imaging. 2023;11(1):51–70.CrossRef Jokar N, Moradhaseli F, Ahmadzadehfar H, Jafari E, Nikeghbalian S, Rasekhi AR, et al. Theranostic approach in liver cancer: an emerging paradigm to optimize personalized medicine. Clin Transl Imaging. 2023;11(1):51–70.CrossRef
6.
Zurück zum Zitat Rüschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald A-K, et al. What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48(12):4042–53.CrossRefPubMedPubMedCentral Rüschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald A-K, et al. What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48(12):4042–53.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Dadgar H, Emami F, Norouzbeigi N, Vafaee MS, Jafari E, Gholamrezanezhad A, et al. Application of [68Ga]PSMA PET/CT in diagnosis and management of prostate cancer patients. Mol Imaging Biol. 2020;22:1062–9.CrossRefPubMed Dadgar H, Emami F, Norouzbeigi N, Vafaee MS, Jafari E, Gholamrezanezhad A, et al. Application of [68Ga]PSMA PET/CT in diagnosis and management of prostate cancer patients. Mol Imaging Biol. 2020;22:1062–9.CrossRefPubMed
8.
Zurück zum Zitat Burgard C, Hoffmann MA, Frei M, Buchholz H-G, Khreish F, Marlowe RJ, et al. Detection efficacy of 68Ga-PSMA-11 PET/CT in biochemical recurrence of prostate cancer with very low PSA levels: a 7-year, two-center “real-world” experience. Cancers. 2023;15(5):1376. Burgard C, Hoffmann MA, Frei M, Buchholz H-G, Khreish F, Marlowe RJ, et al. Detection efficacy of 68Ga-PSMA-11 PET/CT in biochemical recurrence of prostate cancer with very low PSA levels: a 7-year, two-center “real-world” experience. Cancers. 2023;15(5):1376.
9.
Zurück zum Zitat De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, et al. 18F-PSMA-11 versus 68Ga-PSMA-11 positron emission tomography/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial. Eur Urol. 2022;82(5):501–9.CrossRefPubMed De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, et al. 18F-PSMA-11 versus 68Ga-PSMA-11 positron emission tomography/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial. Eur Urol. 2022;82(5):501–9.CrossRefPubMed
10.
Zurück zum Zitat Thomas AH, Jeremy ZG, Isabel EA, Jeremie C, Wolfgang PF, Peter RC. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786. Thomas AH, Jeremy ZG, Isabel EA, Jeremie C, Wolfgang PF, Peter RC. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786.
11.
Zurück zum Zitat Assadi M, Pirayesh E, Rekabpour SJ, Zohrabi F, Jafari E, Nabipour I, et al. 177Lu-PSMA and 177Lu-DOTATATE therapy in a patient with metastatic castration-resistant prostate cancer and neuroendocrine differentiation. Clin Nucl Med. 2019;44(12):978–80. Assadi M, Pirayesh E, Rekabpour SJ, Zohrabi F, Jafari E, Nabipour I, et al. 177Lu-PSMA and 177Lu-DOTATATE therapy in a patient with metastatic castration-resistant prostate cancer and neuroendocrine differentiation. Clin Nucl Med. 2019;44(12):978–80.
12.
Zurück zum Zitat Assadi M, Rezaei S, Jafari E, Rekabpour SJ, Ravanbod MR, Zohrabi F, et al. Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: initial clinical experience after 2 years. World J Nucl Med. 2020;19(01):15–20. Assadi M, Rezaei S, Jafari E, Rekabpour SJ, Ravanbod MR, Zohrabi F, et al. Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: initial clinical experience after 2 years. World J Nucl Med. 2020;19(01):15–20.
13.
Zurück zum Zitat Jafari E, Ahmadzadehfar H, Bagheri D, Amini A, Assadi M. Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C. Nucl Med Commun. 2021;42(3):325–31.CrossRefPubMed Jafari E, Ahmadzadehfar H, Bagheri D, Amini A, Assadi M. Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C. Nucl Med Commun. 2021;42(3):325–31.CrossRefPubMed
14.
Zurück zum Zitat Jafari E, Amini AL, Ahmadzadehfar H, Bagheri D, Assadi M. Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors. Nuklearmedizin-NuclearMedicine. 2021;60(02):99–105. Jafari E, Amini AL, Ahmadzadehfar H, Bagheri D, Assadi M. Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors. Nuklearmedizin-NuclearMedicine. 2021;60(02):99–105.
15.
Zurück zum Zitat Bauckneht M, Bertagna F, Donegani MI, Durmo R, Miceli A, De Biasi V, et al. The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer Prostatic Dis. 2021;24(4):1198–207.CrossRefPubMedPubMedCentral Bauckneht M, Bertagna F, Donegani MI, Durmo R, Miceli A, De Biasi V, et al. The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer Prostatic Dis. 2021;24(4):1198–207.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Moazemi S, Erle A, Lütje S, Gaertner FC, Essler M, Bundschuh RA. Estimating the potential of radiomics features and radiomics signature from pretherapeutic PSMA-PET-CT scans and clinical data for prediction of overall survival when treated with 177Lu-PSMA. Diagnostics. 2021;11(2):186.CrossRefPubMedPubMedCentral Moazemi S, Erle A, Lütje S, Gaertner FC, Essler M, Bundschuh RA. Estimating the potential of radiomics features and radiomics signature from pretherapeutic PSMA-PET-CT scans and clinical data for prediction of overall survival when treated with 177Lu-PSMA. Diagnostics. 2021;11(2):186.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Assadi M, Manafi-Farid R, Jafari E, Keshavarz A, Divband GA, Moradi MM, et al. Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA. Front Oncol. 2022;12:6956. Assadi M, Manafi-Farid R, Jafari E, Keshavarz A, Divband GA, Moradi MM, et al. Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA. Front Oncol. 2022;12:6956.
18.
Zurück zum Zitat Montagne S, Hamzaoui D, Allera A, Ezziane M, Luzurier A, Quint R, et al. Challenge of prostate MRI segmentation on T2-weighted images: inter-observer variability and impact of prostate morphology. Insights Imaging. 2021;12(1):1–12.CrossRef Montagne S, Hamzaoui D, Allera A, Ezziane M, Luzurier A, Quint R, et al. Challenge of prostate MRI segmentation on T2-weighted images: inter-observer variability and impact of prostate morphology. Insights Imaging. 2021;12(1):1–12.CrossRef
19.
Zurück zum Zitat Kendrick J, Francis RJ, Hassan GM, Rowshanfarzad P, Ong JSL, Ebert MA. Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [68Ga] Ga-PSMA-11 PET/CT images. Eur J Nucl Med Mol Imaging. 2022;50(1):67–79.CrossRefPubMedPubMedCentral Kendrick J, Francis RJ, Hassan GM, Rowshanfarzad P, Ong JSL, Ebert MA. Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [68Ga] Ga-PSMA-11 PET/CT images. Eur J Nucl Med Mol Imaging. 2022;50(1):67–79.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Jarrett D, Stride E, Vallis K, Gooding MJ. Applications and limitations of machine learning in radiation oncology. Br J Radiol. 2019;92(1100):20190001.CrossRefPubMedPubMedCentral Jarrett D, Stride E, Vallis K, Gooding MJ. Applications and limitations of machine learning in radiation oncology. Br J Radiol. 2019;92(1100):20190001.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Zhao Y, Gafita A, Vollnberg B, Tetteh G, Haupt F, Afshar-Oromieh A, et al. Deep neural network for automatic characterization of lesions on 68 Ga-PSMA-11 PET/CT. Eur J Nucl Med Mol Imaging. 2020;47:603–13.CrossRefPubMed Zhao Y, Gafita A, Vollnberg B, Tetteh G, Haupt F, Afshar-Oromieh A, et al. Deep neural network for automatic characterization of lesions on 68 Ga-PSMA-11 PET/CT. Eur J Nucl Med Mol Imaging. 2020;47:603–13.CrossRefPubMed
22.
Zurück zum Zitat Liu X, Han C, Cui Y, Xie T, Zhang X, Wang X. Detection and segmentation of pelvic bones metastases in MRI images for patients with prostate cancer based on deep learning. Front Oncol. 2021;11: 773299.CrossRefPubMedPubMedCentral Liu X, Han C, Cui Y, Xie T, Zhang X, Wang X. Detection and segmentation of pelvic bones metastases in MRI images for patients with prostate cancer based on deep learning. Front Oncol. 2021;11: 773299.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Trägårdh E, Enqvist O, Ulén J, Hvittfeldt E, Garpered S, Belal SL, et al. Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians. Eur J Nucl Med Mol Imaging. 2022;49(10):3412–8.CrossRefPubMedPubMedCentral Trägårdh E, Enqvist O, Ulén J, Hvittfeldt E, Garpered S, Belal SL, et al. Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians. Eur J Nucl Med Mol Imaging. 2022;49(10):3412–8.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods. 2021;18(2):203–11.CrossRefPubMed Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods. 2021;18(2):203–11.CrossRefPubMed
25.
Zurück zum Zitat Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J-C, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30(9):1323–41.CrossRefPubMedPubMedCentral Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J-C, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30(9):1323–41.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Can Res. 2018;78(16):4786–9.CrossRef Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Can Res. 2018;78(16):4786–9.CrossRef
27.
Zurück zum Zitat Gavade AB, Nerli R, Kanwal N, Gavade PA, Pol SS, Rizvi STH. Automated diagnosis of prostate cancer using mpMRI images: a deep learning approach for clinical decision support. Computers. 2023;12(8):152.CrossRef Gavade AB, Nerli R, Kanwal N, Gavade PA, Pol SS, Rizvi STH. Automated diagnosis of prostate cancer using mpMRI images: a deep learning approach for clinical decision support. Computers. 2023;12(8):152.CrossRef
28.
Zurück zum Zitat Liu X, Han C, Cui Y, Xie T, Zhang X, Wang X. Detection and segmentation of pelvic bones metastases in MRI images for patients with prostate cancer based on deep learning. Front Oncol. 2021;11:773299. Liu X, Han C, Cui Y, Xie T, Zhang X, Wang X. Detection and segmentation of pelvic bones metastases in MRI images for patients with prostate cancer based on deep learning. Front Oncol. 2021;11:773299.
29.
Zurück zum Zitat Lee JJ, Yang H, Franc BL, Iagaru A, Davidzon GA. Deep learning detection of prostate cancer recurrence with 18 F-FACBC (fluciclovine, Axumin®) positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47:2992–7.CrossRefPubMed Lee JJ, Yang H, Franc BL, Iagaru A, Davidzon GA. Deep learning detection of prostate cancer recurrence with 18 F-FACBC (fluciclovine, Axumin®) positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47:2992–7.CrossRefPubMed
30.
Zurück zum Zitat Gafita A, Bieth M, Krönke M, Tetteh G, Navarro F, Wang H, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT. J Nucl Med. 2019;60(9):1277–83.CrossRefPubMedPubMedCentral Gafita A, Bieth M, Krönke M, Tetteh G, Navarro F, Wang H, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT. J Nucl Med. 2019;60(9):1277–83.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H. Correlations between whole body volumetric parameters of 68 Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients. Ann Nucl Med. 2021;35:540–8.CrossRefPubMed Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H. Correlations between whole body volumetric parameters of 68 Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients. Ann Nucl Med. 2021;35:540–8.CrossRefPubMed
32.
Zurück zum Zitat Michalski K, Mix M, Meyer PT, Ruf J. Determination of whole-body tumour burden on [68Ga] PSMA-11 PET/CT for response assessment of [177Lu] PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy. Nuklearmedizin-NuclearMedicine. 2019;58(06):443–50. Michalski K, Mix M, Meyer PT, Ruf J. Determination of whole-body tumour burden on [68Ga] PSMA-11 PET/CT for response assessment of [177Lu] PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy. Nuklearmedizin-NuclearMedicine. 2019;58(06):443–50.
33.
Zurück zum Zitat Stanzione A, Ponsiglione A, Alessandrino F, Brembilla G, Imbriaco M. Beyond diagnosis: is there a role for radiomics in prostate cancer management? Eur Radiol Exp. 2023;7(1):13.CrossRefPubMedPubMedCentral Stanzione A, Ponsiglione A, Alessandrino F, Brembilla G, Imbriaco M. Beyond diagnosis: is there a role for radiomics in prostate cancer management? Eur Radiol Exp. 2023;7(1):13.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Belal SL, Frantz S, Minarik D, Enqvist O, Wikström E, Edenbrandt L, et al., editors. Applications of artificial intelligence in PSMA PET/CT for prostate cancer imaging. Elsevier; 2023. Belal SL, Frantz S, Minarik D, Enqvist O, Wikström E, Edenbrandt L, et al., editors. Applications of artificial intelligence in PSMA PET/CT for prostate cancer imaging. Elsevier; 2023.
35.
Zurück zum Zitat Shiri I, Salimi Y, Maghsudi M, Jenabi E, Harsini S, Razeghi B, et al. Differential privacy preserved federated transfer learning for multi-institutional 68Ga-PET image artefact detection and disentanglement. Eur J Nucl Med Mol Imaging. 2023;51(1):40–53. Shiri I, Salimi Y, Maghsudi M, Jenabi E, Harsini S, Razeghi B, et al. Differential privacy preserved federated transfer learning for multi-institutional 68Ga-PET image artefact detection and disentanglement. Eur J Nucl Med Mol Imaging. 2023;51(1):40–53.
36.
Zurück zum Zitat Moazemi S, Khurshid Z, Erle A, Lütje S, Essler M, Schultz T, et al. Machine learning facilitates hotspot classification in PSMA-PET/CT with nuclear medicine specialist accuracy. Diagnostics. 2020;10(9):622.CrossRefPubMedPubMedCentral Moazemi S, Khurshid Z, Erle A, Lütje S, Essler M, Schultz T, et al. Machine learning facilitates hotspot classification in PSMA-PET/CT with nuclear medicine specialist accuracy. Diagnostics. 2020;10(9):622.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Erle A, Moazemi S, Lütje S, Essler M, Schultz T, Bundschuh RA. Evaluating a machine learning tool for the classification of pathological uptake in whole-body PSMA-PET-CT scans. Tomography. 2021;7(3):301–12.CrossRefPubMedPubMedCentral Erle A, Moazemi S, Lütje S, Essler M, Schultz T, Bundschuh RA. Evaluating a machine learning tool for the classification of pathological uptake in whole-body PSMA-PET-CT scans. Tomography. 2021;7(3):301–12.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Moazemi S, Erle A, Khurshid Z, Lütje S, Muders M, Essler M, et al. Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters. Ann Transl Med. 2021;9(9):818. Moazemi S, Erle A, Khurshid Z, Lütje S, Muders M, Essler M, et al. Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters. Ann Transl Med. 2021;9(9):818.
39.
Zurück zum Zitat European Society of Radiology communications@ my ESRo. Summary of the European Directive 2013/59/Euratom: essentials for health professionals in radiology. Insights Imaging. 2015;6:411–7. European Society of Radiology communications@ my ESRo. Summary of the European Directive 2013/59/Euratom: essentials for health professionals in radiology. Insights Imaging. 2015;6:411–7.
40.
Zurück zum Zitat Xue S, Gafita A, Dong C, Zhao Y, Tetteh G, Menze BH, et al. Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy. Eur J Nucl Med Mol Imaging. 2022;49(12):4064–72.CrossRefPubMedPubMedCentral Xue S, Gafita A, Dong C, Zhao Y, Tetteh G, Menze BH, et al. Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy. Eur J Nucl Med Mol Imaging. 2022;49(12):4064–72.CrossRefPubMedPubMedCentral
Metadaten
Titel
A convolutional neural network–based system for fully automatic segmentation of whole-body [68Ga]Ga-PSMA PET images in prostate cancer
verfasst von
Esmail Jafari
Amin Zarei
Habibollah Dadgar
Ahmad Keshavarz
Reyhaneh Manafi-Farid
Habib Rostami
Majid Assadi
Publikationsdatum
14.12.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-023-06555-z

Weitere Artikel der Ausgabe 5/2024

European Journal of Nuclear Medicine and Molecular Imaging 5/2024 Zur Ausgabe